LION POINT CAPITAL, LP
0
followers
·
Follow
NEW YORK NY
Investment Advisor
Hedge Fund
Activist Investor
Lion Point Capital is based out of New York. Lion Point Capital is a hedge fund with 6 clients and discretionary assets under management (AUM) of $517,721,393 (Form ADV from 2024-10-08). Their last reported 13F filing for Q3 2024 included $44,906,962 in managed 13F securities
and a top 10 holdings concentration of 83.47%. Lion Point Capital's largest holding is iShares Russell 2000 ETF with shares held of 82,500. Whalewisdom has at least 37 13F filings, 19 13D filings, 18 13G filings, and 4 Form 4 filings
Investment Strategy
The investment strategies employed by the Funds involve a wide range of financial instruments, including stocks, bonds, bank loans, swaps, options, futures, forwards, swaptions, private equity, and correlation products. The Funds' trading mandates encompass virtually every type of asset, investment interest, security, or property that can be traded or purchased.
The Funds' investment objective is to achieve attractive long-term, absolute returns across market cycles while preserving capital through security selection, in-depth analysis, and rigorous risk management. The Funds may invest in all manner of securities, financial instruments, and obligations, including equity and debt securities, bank debt, trade debt, sovereign debt, contractual and litigation claims, market and sector indices, and derivatives. The Funds may invest in issuers domiciled within or outside the United States.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-09-30
Top Buys (13F)
| Name | % Change |
|---|---|
| BHVN Biohaven Ltd | 3.94% |
| IRON Disc Medicine Inc | 0.84% |
| BNTC Benitec Biopharma In | 0.8% |
| ARQT Arcutis Biotherapeut | 0.73% |
| BLUE Bluebird Bio Inc | 0.61% |
2024-09-30
Top Sells (13F)
| Name | % Change |
|---|---|
| XBI SPDR Biotech ETF (PUT) | 8.45% |
| ARDX Ardelyx Inc | 5.9% |
| NBIX Neurocrine Bioscienc | 2.1% |
| MRNS Marinus Pharmaceutic | 1.79% |
| NFYS Enphys Acquisition C | 1.56% |
2024-09-30
13F Holdings Summary
| Name | $ Change |
|---|---|
| IWM iShares Russell 2000(PUT) | 40.58% |
| INSM Insmed Inc | 8.49% |
| GERN Geron Corp | 6.37% |
| ARDX Ardelyx Inc | 5.68% |
| MIST Milestone Pharmaceut | 5.6% |
2024-09-30
13F Activity
| Market Value | $44.9m, Prior: $54.9m |
| Inflows (Outflows) as % of Total MV | (-27.3712)% |
| New Purchases | 4 stocks |
| Added To | 3 stocks |
| Sold out of | 6 stocks |
| Reduced holdings in | 8 stocks |
| Top 10 Holdings % | 83.47% |
| Turnover %[1] | 32.26% |
| Turnover Alt %[2] | 8.35% |
| Time Held Top 20 | 3.7 quarters |
| Time Held Top 10 | 4.2 quarters |
| Time Held All | 5.84 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-09-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-09-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-09-30